Clinical Trial Update: Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on ThisCART19A in patients with refractory or relapsed B cell lymphoma across Phase 1 and Phase 2, reporting on safety, efficacy, and ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Relapsed Cell Lymphoma

Drugs mentioned

• ThisCART19A (ThisCART19A)

Snippet

Sponsor: Chongqing University Cancer Hospital | Conditions: Refractory or Relapsed B Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN